Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma
Trial Details
- NCT ID
- NCT06464861
- Phase
- PHASE1
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- RECRUITING
- Cancer Type
- Mantle Cell Lymphoma Lymphoma
- Interventions
- Locations (sample)
- Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
- Age 18-75 years old, no gender limit;
- Histologically diagnosed as diffuse large B-cell lymphoma (DLBCL), transforming follicular lymphoma (TFL), primary mediastinal B-cell lymphoma (PMB…
- Refractory or relapsed DLBCL refers to the failure to achieve complete remission after 2-line treatment; disease progression during any treatment, …
- Refractory or relapsed MCL must be resistant to or intolerable to BTK inhibitors;
For full eligibility, visit ClinicalTrials.gov.